Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Could Gold Rally Above $3750 Before December 2019?

We asked our researchers a question recently, “Could Gold rally above $3750 before the end of 2019?”. We wanted to see what type of research they would bring to the table that could support a move like this of nearly 200% from current levels. We wanted to...

King Dollar Rides Higher Creating Pressures On Foreign Economies

One of the biggest movers of the day on Friday was the US dollar. The US stock market appeared very weak prior to the opening bell and precious metals, especially gold, appeared to be rocketing higher. Almost right from the open, the markets washed out the fear and changed dir...

Us Stocks Seem To Be Following Our Predictions – Get Ready (Part I)

As we near the important date of August 19, 2019, and we watch how the markets are reacting based on our earlier predictions, it is becoming evident that the US stock markets and global stock markets are following our predictions very well. The fact that these markets are doin...

Insmed Shares Trade 40% Higher on Phase 2 Top-Line Bronchiectasis Trial Data

Insmed Inc.'s shares traded higher today after the company reported positive top-line results from its Phase 2 WILLOW Study of INS1007 in patients with non-cystic fibrosis bronchiectasis. Global biopharmaceutical company Insmed Inc. (INSM:NASDAQ) , which is...

Gold Leads, Will the Rest Follow?

The natural resource landscape has shifted dramatically since the end of 2018. At the time, we were still nursing our wounds from an unexpectedly vicious 2018 and hoping to avoid a repeat performance in 2019. I did speculate that "we may have already exited the bear mar...

Real Estate Crash The Next Shoe To Drop – Part II

As we continue to delve into the looming Real Estate crisis that will likely hit the US and globe over the next 12 to 24+ months, we want to focus on the human psychological process of dealing with a crisis event and how that relates to economic engagement. In the first part...

Don’t Get Caught in the High-Grade Gold Trap

In gold exploration, high-grade discoveries excite the market. This is because retail investors expect a high-grade deposit, if it ever becomes a mine, to be more profitable. But a closer look at high margin projects shows that high grade isn’t always king. ...

Deflation or Inflation: Gold Doesn't Care

Rudi Fronk and Jim Anthony, cofounders of Seabridge Gold, discuss recession, central bank panic and an outrageous gold price. In our view, gold investors should settle back with some popcorn and enjoy the coming fireworks, which will include the best gold bull market ...

Will 2020 be junior mining’s year?

Another year of covering commodities and select junior mining stocks is all but done and dusted. We’ve seen palladium prices more than double those of platinum, its sister metal, on tight supply and high demand for catalytic converters in gas-powered ve...

A Battle for the Ages

As I was watching the pompom news channel (CNBC), they went into full damage control over Thursday's massacre, and I thought to myself, "What markets or media bullet points do 'the boys' need to control today in order to avoid a weekly sell signal and ensuing panic?" In...
1 2